Galectin Therapeutics
GALT
GALT
94 hedge funds and large institutions have $13M invested in Galectin Therapeutics in 2024 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 35 increasing their positions, 12 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
23% less call options, than puts
Call options by funds: $5.86M | Put options by funds: $7.59M
52% less capital invested
Capital invested by funds: $26.8M → $13M (-$13.8M)
Holders
94
Holding in Top 10
–
Calls
$5.86M
Puts
$7.59M
Top Buyers
| 1 | +$118K | |
| 2 | +$73.6K | |
| 3 | +$57.7K | |
| 4 |
Morgan Stanley
New York
|
+$56.8K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$48.3K |
Top Sellers
| 1 | -$451K | |
| 2 | -$144K | |
| 3 | -$91.9K | |
| 4 |
ECM
ExodusPoint Capital Management
New York
|
-$81K |
| 5 |
Squarepoint
New York
|
-$75.4K |